Piramal Pharma Limited has announced receiving an improved Environment, Social, and Governance (ESG) rating for FY 2024-25, marking a positive development in the company's sustainability journey. The pharmaceutical company disclosed this information to stock exchanges on April 6, 2026, as part of its regulatory compliance obligations.

ESG Rating Performance

NSE Sustainability Ratings and Analytics Limited has assigned an ESG rating of 64 to Piramal Pharma Limited for FY 2024-25. This rating assessment was based on data made available by the company in the public domain for that financial year.

Rating Methodology and Independence

The company emphasized that it did not engage NSE Sustainability for obtaining this ESG rating. NSE Sustainability voluntarily prepared the assessment report by considering the ESG factors reported by Piramal Pharma Limited. This independent evaluation approach ensures objectivity in the rating process.

The rating reflects the company's ongoing commitment to sustainability and responsible operations across environmental, social, and governance parameters. The improvement from the previous score of 61 to 64 indicates enhanced performance in ESG practices.

Regulatory Disclosure

Piramal Pharma Limited made this disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has also made this information available on its official website at piramalpharma.com for stakeholder access.

The ESG rating information has been published on NSE Sustainability's website, providing transparency and accessibility to investors and other stakeholders interested in the company's sustainability performance.

Piramal Pharma Limited has successfully completed its strategic acquisition of Kenalog, a branded commercial injectable product, marking a significant expansion of its pharmaceutical portfolio. The acquisition was finalized on 1st April, 2026, through the company's step-down wholly owned subsidiary, Piramal Critical Care B.V.

Acquisition Details

The transaction involved the acquisition of Kenalog and its associated brands from Bristol-Myers Squibb Company (BMS). This completion follows the company's earlier market intimation dated 28th January, 2026, which had initially disclosed the planned acquisition to regulatory authorities.

Strategic Impact

The successful completion of the Kenalog acquisition represents a strategic enhancement to Piramal Pharma's existing pharmaceutical offerings. The transaction specifically strengthens the company's Complex Hospital Generics portfolio, positioning it for enhanced competitiveness in specialized therapeutic segments.

Market Expansion

With this acquisition, Piramal Pharma reinforces its presence across multiple key international markets. The expanded portfolio will strengthen the company's footprint in:

• United States market
• European markets
• Asia Pacific region

The acquisition aligns with the company's strategy to expand its presence in critical care and hospital-based pharmaceutical products, leveraging the established brand recognition and market positioning of the Kenalog product line.

Regulatory Compliance

The acquisition completion was disclosed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made to both BSE Limited and National Stock Exchange of India Limited, ensuring full regulatory compliance and transparency with stakeholders.